Roughly $12 million worth of HIV-prevention drugs and contraceptives purchased by the U.S. Agency for International ...

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

HIV/AIDS remains a major public health threat worldwide, with an estimated 39.9 million people living with the disease at the ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

By bolstering immune cells, researchers at ViiV Healthcare in Branford have designed long-acting drugs that prevent infection ...